| Rohan Palekar |
Rohan Palekar is currently the Chief Executive Officer & Director at 89bio, Inc. He is also the Chairman at Aim High For High School and an Independent Director at Neurogene, Inc. Previously, he served as the President & Chief Executive Officer at Avanir Pharmaceuticals, Inc. from 2016 to 2017. He was also the Chief Executive Officer at Xenerex Biosciences and an Independent Director at Neoleukin Therapeutics, Inc. Additionally, he held the position of Vice President-Dermatology Sales & Marketing at Centocor, Inc. from 2001 to 2007 and Chief Commercial Officer at Medivation LLC (California) from 2008 to 2011. Mr. Palekar completed his undergraduate and graduate studies at the University of Mumbai and holds an MBA from the Tuck School of Business at Dartmouth. |
| Wenyan Wang |
Wenyan Wang is currently working as the Vice President-Clinical Development at 89bio, Inc. Prior to this role, Dr. Wang obtained a doctorate degree from Iowa State University and a graduate degree from Sichuan University. |
| Quoc Le-Nguyen |
Quoc Le-Nguyen is currently the Chief Technical Operations Officer & Head-Quality at 89bio, Inc. He previously worked as the Vice President-Manufacturing Operations at Bayer AG from 2007 to 2013 and as the SVP, Global Head-Technical Operations & Quality at Aduro BioTech, Inc. from 2015 to 2018. Mr. Le-Nguyen completed his undergraduate degree at the University of California. |
| Ryan Stephen Martins |
Ryan Stephen Martins is currently the Chief Financial Officer at 89bio, Inc. He previously held positions at Chiron Corp., Lehman Brothers, Inc., Ultragenyx Pharmaceutical, Inc., Jefferies LLC, Barclays Capital, Inc., FM Partners Holdings LLC, and Revolution Medicines, Inc. He has a graduate degree from Virginia Polytechnic Institute & State University, undergraduate and graduate degrees from the University of Mumbai, an MBA from Haas School of Business, and an undergraduate degree from St. Xavier's College. |
| Steven M. Altschuler |
Steven M. Altschuler was the founder of Spark Therapeutics, Inc. (founded in 2013) where he served as Chairman from 2013 to 2019. He is also the founder of Corner Therapeutics, Inc. Dr. Altschuler's current job positions include Chairman at Stellular Bio, Inc., AsclepiX. Therapeutics LLC, Azura Ophthalmics Pty Ltd., 89bio, Inc., Lexeo Therapeutics, Inc., and Independent Director at WW International, Inc. He also holds director positions at Free Library of Philadelphia, The GAVI Campaign, Affinivax, Inc., Imvax, Inc., Innovative Genomics Institute, The Brigham & Women's Hospital, Inc., and Brigham & Women's Physician Group. Dr. Altschuler's former job positions include President & Chief Executive Officer at The Children's Hospital of Philadelphia Foundation from 2000 to 2015, President & Chief Executive Officer at University of Miami Health System from 2016 to 2017, Chief Executive Officer at The Children's Hospital of Philadelphia from 2000 to 2015, Chairman-Pediatrics Department at Perelman School of Medicine, Independent Director at Adtalem Global Education, Inc. from 2018 to 2020, Director at University Healthsystem Consortium, Inc., Director at Mead Johnson Nutrition Co. from 2009 to 2017, Independent Director at Mead Johnson Nutrition Co. from 2011 to 2017, Independent Director at Orchard Therapeutics Plc from 2020 to 2024, and Executive Vice President-Healthcare at Miami University from 2016 to 2017. Dr. Altschuler's education includes undergraduate and doctorate degrees from Case Western Reserve University. Dr. Altschuler is also the founder of Corner Therapeutics, Inc... |
| Paul Shin |
Paul Shin's current job is as the VP-Research & Development Operations at 89bio, Inc. His former jobs include being the Vice President-Research & Development Operations at Avanir Pharmaceuticals, Inc. from 2011 to 2016, the Vice President-Global Clinical Operations at Intercept Pharmaceuticals, Inc. from 2018 to 2020, and the SVP-Global Research & Development Operations at Nestle Health Science SA from 2016 to 2018. Mr. Shin obtained his undergraduate degree from the University of California. |
| Harry H. Mansbach |
Harry H. Mansbach is currently the Chief Medical Officer at 89bio, Inc. He previously worked as the Director of Clinical Development & Neurosciences at GlaxoSmithKline LLC and as the Senior VP & Head of Global Drug Development at Bausch Health Americas, Inc. From 2004 to 2006, he served as the Chief Medical Officer & VP of Clinical Development at RespireRx Pharmaceuticals, Inc. He also held the position of Head of Global Clinical Development at Ultragenyx Pharmaceutical, Inc. in 2018. Additionally, he was a Member of the Neurology Department at Henry Ford Health System and Vice President of Medical Affairs at Medivation LLC from 2009 to 2015. Dr. Mansbach obtained a doctorate degree from Duke University and an undergraduate degree from Yale University. |
| Edward Morrow Atkinson |
Edward Morrow Atkinson is an Independent Director at 89bio, Inc. and the Chief Technical Operations Officer & Executive VP at Vertex Pharmaceuticals, Inc. He previously served as the Chief Scientific Officer & Vice President at Catalent Indiana LLC and the Senior VP-Global Manufacturing Operations at Bristol Myers Squibb Co. Dr. Atkinson holds a doctorate degree from Stanford University and an undergraduate degree from Indiana University. |
| Derek DiRocco |
Derek DiRocco is currently an Independent Director at Werewolf Therapeutics, Inc., a Director at Suzhou Connect Biopharma Co. Ltd., an Independent Director at 89bio, Inc., a Non-Executive Director at Achilles Therapeutics UK Ltd., an Independent Director at Acrivon Therapeutics, Inc., a Director at 89Bio Ltd., an Independent Director at Mineralys Therapeutics, Inc., and a Partner at RA Capital Management LP and RA Capital Management LP (Private Equity). In the past, Dr. DiRocco served as an Independent Director at iTeos Therapeutics, Inc. and CANbridge Pharmaceuticals Inc. from 2020 to 2023, an Independent Director at Day One Biopharmaceuticals, Inc., an Independent Non-Executive Director at Achilles Therapeutics Plc from 2019 to 2022, a Director at Canbridge Pharmaceuticals, Inc. (United States), and an Independent Non-Executive Director at Connect Biopharma Holdings Ltd.Dr. DiRocco completed his undergraduate degree at the College of the Holy Cross (Massachusetts) in 2002 and obtained a doctorate degree from the University of Washington in 2009. |
| Martin Babler |
Martin Babler is currently the Chairman, President & Chief Executive Officer at Alumis, Inc. He is also a Director at the Biotechnology Innovation Organization, Prelude Therapeutics, Inc., Omega Alpha SPAC, Sardona Therapeutics, Inc., and 89bio, Inc. In the past, Mr. Babler served as the President & Chief Executive Officer at Talima Therapeutics, Inc. from 2010 to 2011. He was also the President, Chief Executive Officer & Director at Principia Biopharma, Inc. from 2019 to 2020. Additionally, he held the position of Vice President-Immunology Sales & Marketing at Genentech, Inc. from 2006 to 2007 and worked as a Principal at Eli Lilly & Co. from 1991 to 1998. |
| Michael R. Hayden |
Michael R. Hayden is the founder of Aspreva Pharmaceuticals Corp. (founded in 2002) and Centre for Molecular Medicine & Therapeutic (founded in 1992). He is also the founder of NeuroVir Therapeutic, Inc., Prilenia Therapeutics Development Ltd., and 89bio, Inc. (founded in 2018). Currently, Dr. Hayden holds positions as an Independent Director at Ionis Pharmaceuticals, Inc. (since 2018), a Non-Executive Director at Oxford Biomedica Plc (since 2021), and a Director-Translational Laboratory at the National University of Singapore. He is also a Scientific Director at the Canadian Genetics Diseases Network (since 1990), a Director at the Royal Society of Canada (since 1995), a Lead Independent Director at AbCellera Biologics, Inc. (since 2019), a Director & Program Director at the Translational Laboratory in Genetic Medicine, a Venture Advisor at Andera Partners SCA (since 2018), a Professor at the University of British Columbia (since 1983), a Venture Partner at Forbion Capital Partners Management Holding BV (since 2022), and a Member of the American Society of Clinical Investigation (since 1992). In his former roles, Dr. Hayden served as a Director at Lycera Corp., Many Bright Ideas Technologies, Inc., and the Agency for Science, Technology & Research. He was also a Director at the Michael Smith Foundation for Health Research (2011-2012), an Independent Director at Aurinia Pharmaceuticals, Inc. (2018-2021), and the Chief Scientific Officer at Teva Pharmaceutical Industries Ltd. (2013-2017). Additionally, he was a President & Chief Scientific Officer at GlobaR&D Co., Ltd. Dr. Hayden obtained his undergraduate and doctorate degrees from the University of Cape Town in 1975 and 1979, respectively. Dr. Hayden is also the founder of NeuroVir Therapeutic, Inc., Prilenia Therapeutics Development Ltd... |
| Kathy D. LaPorte |
Kathy D. LaPorte is the founder. She founded New Leaf Venture Partners LLC in 2005, where she held the title of Partner. Ms. LaPorte is also the founder of HealthTech Capital Co...Ms. LaPorte's current job(s) include being a Director at Aesthetic Sciences Corp., Precipio Diagnostics LLC, Bolt Biotherapeutics, Inc., Precipio, Inc., Elysium Therapeutics, Inc., 89bio, Inc., Q32 Bio Operations, Inc., D2G Oncology, Inc., CERo Therapeutics Holdings, Inc., and Q32 Bio, Inc.Ms. LaPorte's former job(s) include being the Chief Executive Officer at Nodality, Inc., a Director at Cytyc Prenatal Products Corp., Onyx Pharmaceuticals, Inc., ISTA Pharmaceuticals, Inc., VNUS Medical Technologies, Inc., Transcept Pharmaceuticals, Inc. (Old), eHealth, Inc., Affymax, Inc., Cellgate, Inc., Prometheus Laboratories, Inc., eHealthInsurance Services, Inc., the California Institute for Regenerative Medicine, Pearl Therapeutics, Inc., Transcept Pharma, Inc., Phoenix Biotech Acquisition Corp., and First Boston Corp. She was also a General Partner at Sprout Group and Credit Suisse Securities (USA) LLC, and the President of the Western Association of Venture Capitalists. Ms. LaPorte's education history includes an undergraduate degree from Yale University in 1983 and an MBA from Stanford Graduate School of Business in 1987. |
| Lota S. Zoth |
Lota S. Zoth is currently an Independent Director at 89bio, Inc., Lumos Pharma, Inc., enGene Holdings, Inc., and Inovio Pharmaceuticals, Inc. Previously, Ms. Zoth served as the Chairman of Zymeworks BC, Inc. from 2019 to 2022. Ms. Zoth was also the Chairman of Orexigen Therapeutics, Inc. from 2018 to 2019. Additionally, Ms. Zoth held positions as an Independent Director at NewLink Genetics Corp., a Director at Aeras Global TB Vaccine Foundation from 2011 to 2018, a Non-Executive Director at Hyperion Therapeutics, Inc. in 2015, a Director at Ikaria, Inc. from 2007 to 2014, an Independent Director at Spark Therapeutics, Inc. from 2016 to 2019, a Senior Independent Non-Executive Director at Niox Group Plc from 2015 to 2019, and the Lead Independent Director at Zymeworks, Inc. from 2016 to 2023. Ms. Zoth also held positions at PepsiCo, Inc., PSINet, Inc., Marriott International, Inc., Ernst & Young LLP (Missouri), Sodexho Marriott Services, Inc., and Medimmune, Inc. Ms. Zoth obtained an undergraduate degree from Texas Tech University. |
